These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33460042)

  • 1. A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients.
    Bird S; Pawlyn C; Nallamilli S; Sriskandarajah P; Kaiser M; Yong K; Popat R; Rabin N; Boyd K
    Br J Haematol; 2020 Dec; 191(5):927-930. PubMed ID: 33460042
    [No Abstract]   [Full Text] [Related]  

  • 2. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
    Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Br J Haematol; 2019 May; 185(3):573-578. PubMed ID: 30125960
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
    Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG
    Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.
    Richardson PG; Schlossman RL; Roy AN; Panneerselvam A; Acharyya S; Sopala M; Lonial S
    Br J Haematol; 2018 Jun; 181(5):628-636. PubMed ID: 29774521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
    Moore DC; Arnall JR; Harvey RD
    J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.
    Elsada A; Adler AI
    Lancet Oncol; 2019 May; 20(5):619-620. PubMed ID: 30981602
    [No Abstract]   [Full Text] [Related]  

  • 10. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
    Mangiacavalli S; Pochintesta L; Ravelli E; Baldini L; Ferretti VV; La Targia ML; Farina L; Cocito F; Cairoli R; Montefusco V; Corso A
    Leuk Lymphoma; 2015 Jun; 56(6):1901-2. PubMed ID: 25347423
    [No Abstract]   [Full Text] [Related]  

  • 11. Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.
    Isoda A; Ishikawa T; Miyazawa Y; Mihara M; Matsumoto M; Sawamura M
    Leuk Lymphoma; 2018 May; 59(5):1277-1278. PubMed ID: 28874073
    [No Abstract]   [Full Text] [Related]  

  • 12. Addition of low-dose decitabine to bortezomib and dexamethasone as second-line therapy in multiple myeloma.
    Li N; Liu L; Xiang P; Liang L; Wang J; Wang Y; Luo S; Song Y; Fang B
    Br J Haematol; 2020 Jun; 189(6):e258-e262. PubMed ID: 32346851
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).
    Waldschmidt JM; Keller A; Ihorst G; Grishina O; Müller S; Wider D; Frey AV; King K; Simon R; May A; Tassone P; Duyster J; Jung M; Raje N; Wäsch R; Engelhardt M
    Haematologica; 2018 Oct; 103(10):e473-e479. PubMed ID: 29674494
    [No Abstract]   [Full Text] [Related]  

  • 14. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
    Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS; Lonial S
    Blood; 2013 Oct; 122(14):2331-7. PubMed ID: 23950178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
    Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
    Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
    Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
    San-Miguel JF; Hungria VTM; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Salwender H; Sopala M; Redhu S; Paul S; Corrado C; Richardson PG
    Br J Haematol; 2017 Oct; 179(1):66-74. PubMed ID: 28653400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
    Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
    J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.